Recombinant nucleic acid molecules are described. The molecules have a sequence or sequences encoding at least two M. tuberculosis antigens. Vectors and compositions containing these molecules are also described. In addition, compositions containing a cocktail of recombinant nucleic acid molecules h
Recombinant nucleic acid molecules are described. The molecules have a sequence or sequences encoding at least two M. tuberculosis antigens. Vectors and compositions containing these molecules are also described. In addition, compositions containing a cocktail of recombinant nucleic acid molecules having a sequence or sequences encoding one or more M. tuberculosis antigens are described. Methods of eliciting an immune response using these molecules and compositions are also described.
대표청구항▼
What is claimed is: 1. A method for eliciting an immune response against M. tuberculosis in a human subject, said method comprising: (a) obtaining a vector construct, wherein the vector construct comprises a recombinant polynucleotide comprising a plurality of sequences each encoding a Mycobacteriu
What is claimed is: 1. A method for eliciting an immune response against M. tuberculosis in a human subject, said method comprising: (a) obtaining a vector construct, wherein the vector construct comprises a recombinant polynucleotide comprising a plurality of sequences each encoding a Mycobacterium tuberculosis antigen and each operably linked to control sequences suitable for expression in the subject; and (b) administering said vector construct to the human subject whereby said antigens are expressed in the human subject at sufficient levels to elicit an immune response. 2. The method of claim 1, further comprising administering at least one secondary composition in a boosting step to said subject wherein the secondary composition contains one or more nucleic acid molecules encoding said plurality of Mycobacterium tuberculosis antigens, or the secondary composition contains said plurality of Mycobacterium tuberculosis antigens. 3. The method of claim 2, wherein the secondary composition comprises at least one culture filtrate protein antigen of M. tuberculosis. 4. The method of claim 2, wherein the secondary composition comprises at least one isolated subunit of a M. tuberculosis protein. 5. The method of claim 2, wherein the secondary composition comprises a live attenuated vaccine derived from a Mycobacterium species. 6. The method of claim 5, wherein the live attenuated vaccine is BCG. 7. A method for eliciting an immune response against M. tuberculosis in a human subject, said method comprising: (a) obtaining a composition containing a plurality of recombinant polynucleotides each comprising a sequence encoding a Mycobacterium tuberculosis antigen operably linked to control sequences suitable for expression in the subject; and (b) administering the composition to the human subject whereby each said antigen is expressed in the human subject at sufficient levels to elicit an immune response. 8. The method of claim 7, further comprising administering at least one secondary composition in a boosting step to said subject wherein the secondary composition contains nucleic acid molecules encoding said Mycobacterium tuberculosis antigen, or the secondary composition contains said Mycobacterium tuberculosis antigen. 9. The method of claim 8, wherein the secondary composition comprises at least one culture filtrate protein antigen of M. tuberculosis. 10. The method of claim 8, wherein the secondary composition comprises at least one isolated subunit of a M. tuberculosis protein. 11. The method of claim 8, wherein the secondary composition comprises a live attenuated vaccine derived from a Mycobacterium species. 12. The method of claim 11, wherein the live attenuated vaccine is BCG. 13. The method of claim 1 or claim 7, wherein the administering is transdermal administration. 14. A method for eliciting an immune response to M. tuberculosis in a human subject, said method comprising: (a) providing a core carrier with a vector construct, wherein the vector construct comprises a recombinant polynucleotide comprising a plurality of sequences each encoding a Mycobacterium tuberculosis antigen and each operably linked to control sequences suitable for expression in the subject; and (b) administering the coated core carrier to the human subject using a particle-mediated delivery technique, wherein the M. tuberculosis antigens are expressed in the human subject at sufficient levels to elicit an immune response. 15. The method of claim 14, wherein the core carrier has an average diameter of about 0.5 to about 5 μm and a density sufficient to allow delivery into the subject. 16. The method of claim 14, wherein the core carrier is comprised of a metal. 17. The method of claim 16, wherein the metal is gold. 18. The method of claim 14, wherein step (b) is repeated. 19. The method of claim 14, further comprising administering at least one secondary composition in a boosting step to said subject wherein the secondary composition contains one or more nucleic acid molecules encoding said plurality of Mycobacterium tuberculosis antigens, or the secondary composition contains said plurality of Mycobacterium tuberculosis antigens. 20. The method of claim 19, where in the secondary composition comprises at least one culture filtrate protein antigen of M. tuberculosis. 21. The method of claim 19, wherein the secondary composition comprises at least one isolated subunit of a M. tuberculosis protein. 22. The method of claim 19, wherein the secondary composition comprises a live attenuated vaccine derived from a Mycobacterium species. 23. The method of claim 22, wherein the live attenuated vaccine is BCG. 24. A method for eliciting an immune response to M. tuberculosis in a human subject, said method comprising: (a) providing a core carrier coated with a composition containing a plurality of recombinant polynucleotides each comprising a sequence encoding a Mycobacterium tuberculosis antigen operably linked to control sequences suitable for expression in the subject; and (b) administering the coated core carrier to the human subject using a particle-mediated delivery technique, wherein the M. tuberculosis antigens are expressed in the human subject at sufficient levels to elicit an immune response. 25. The method of claim 24, wherein the core carrier has an average diameter of about 0.5 to about 5 μm and a density sufficient to allow delivery into the subject. 26. The method of claim 24, wherein the core carrier is comprised of a metal. 27. The method of claim 26, wherein the metal is gold. 28. The method of claim 24, wherein step (b) is repeated. 29. The method of claim 24, further comprising administering at least one secondary composition in a boosting step to said subject wherein the secondary composition contains one or more nucleic acid molecules encoding said plurality of Mycobacterium tuberculosis antigens, or the secondary composition contains said plurality of Mycobacterium tuberculosis antigens. 30. The method of claim 29, wherein the secondary composition comprises at least one culture filtrate protein antigen of M. tuberculosis. 31. The method of claim 29, wherein the secondary composition comprises at least one isolated subunit of a M. tuberculosis protein. 32. The method of claim 29, wherein the secondary composition comprises a live attenuated vaccine derived from a Mycobacterium species. 33. The method of claim 32, wherein the live attenuated vaccine is BCG.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (33)
McCabe Dennis E. (Middleton WI) Martinell Brian J. (Madison WI), Apparatus for genetic transformation.
Sanford John C. (Geneva NY) Wolf Edward D. (Ithaca NY) Allen Nelson K. (Newfield NY), Apparatus for transporting substances into living cells and tissues.
Sanford John C. (Geneva NY) Wolf Edward D. (Ithaca NY) Allen Nelson K. (Newfield NY), Biolistic apparatus for delivering substances into cells and tissues in a non-lethal manner.
Flotte Thomas J. (Boston MA) Doukas Apostolos G. (Belmont MA) McAuliffe Daniel J. (Boxford MA) Anderson Therese M. (Oakland CA), Compound delivery using high-pressure impulse transients.
Morgan Jeffrey R. (Brighton MA) Mulligan Richard C. (Cambridge MA), In vivo introduction and expression of foreign genetic material in epithelial cells.
Felgner Philip L. (Rancho Santa Fe CA) Wolff Jon A. (Madison WI) Rhodes Gary H. (Leucadia CA) Malone Robert W. (Chicago IL) Carson Dennis A. (Del Mar CA), Induction of a protective immune response in a mammal by injecting a DNA sequence.
Kapoor Archana (Maison De L. Inde ; 35 Boulvard Jourdan 75014 Paris CA FRX) Munshi Anil (9450 Gilman Dr. ; No. 920573 LaJolla CA 92092-0573), Membrane-associated immunogens of mycobacteria.
Sanford John C. (Geneva) DeVit Michael J. (Geneva NY) Bruner Ronald F. (Sewell NJ) Johnston Stephen A. (Durham NC), Method and apparatus for introducing biological substances into living cells.
Sanford John C. (Geneva NY) Wolf Edward D. (Ithaca NY) Allen Nelson K. (Newfield NY), Method for transporting substances into living cells and tissues.
Sanford John C. (Geneva NY) Wolf Edward D. (Ithaca NY) Allen Nelson K. (Newfield NY), Method for transporting substances into living cells and tissues and apparatus therefor.
Sanford John C. (Geneva NY) Wolf Edward D. (Ithaca NY) Allen Nelson K. (Newfield NY), Method for transporting substances into living cells and tissues and apparatus therefor.
Bellhouse Brian J. (Islip GB2) Sarphie David F. (Witney GB2) Greenford John C. (Abingdon GB2), Method of delivering powder transdermally with needless injector.
Johnston Stephen A. ; Williams R. Sanders ; Sanford John C. ; McElligott Sandra G., Particle-mediated bombardment of DNA sequences into tissue to induce an immune response.
O\Donnell Michael A. (Sudbury MA) Duda Rosemary B. (Carlisle MA) DeWolf William C. (Southborough MA) Aldovini Anna (Winchester MA) Young Richard A. (Winchester MA), Recombinant BCG.
Bloom Barry R. (Hastings on Hudson NY) Davis Ronald W. (Palo Alto CA) Jacobs ; Jr. William R. (Bronx NY) Young Richard A. (Winchester MA) Husson Robert N. (Takoma Park MD), Recombinant mycobacterial vaccine.
Judd Amrit K. (Belmont CA) Bucher Doris J. (New York NY) Popple Steven W. (Brooklyn NY), Synthetic peptides for diagnosis and prevention of influenza virus infection and their use.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.